Zurich Insurance Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Zurich Insurance Group's NBIX Position: Q2 2026 in Review
Zurich Insurance Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 169,806 shares worth $28.6M. The stake represents 0.2% of the portfolio and ranks #124 among its holdings. This is a return to the name: Zurich Insurance Group previously reported a position in NBIX as recently as Q4 2025.
Zurich Insurance Group first reported a position in NBIX in Q2 2025 and has held it in 3 quarters since. The position peaked at $65.2M in Q4 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Zurich Insurance Group held 169,806 shares of Neurocrine Biosciences worth $28.6M as of Q2 2026.
- Neurocrine Biosciences was a new Zurich Insurance Group position in Q2 2026.
- Neurocrine Biosciences made up 0.2% of Zurich Insurance Group's portfolio in Q2 2026, its #124 holding.
- Zurich Insurance Group first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 3 quarters since.
- Zurich Insurance Group's Neurocrine Biosciences position peaked at $65.2M in Q4 2025.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Zurich Insurance Group's 13F filing for Q2 2026, filed 14 Aug 2026.